Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker BDSX
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 5, 2026 | BDSX Biodesix, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 5, 2026 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 5, 2026 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 20, 2026 | BDSX Biodesix, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 4, 2026 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 26, 2026 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 12, 2026 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K/A | 8-K ↗ |
| Nov 3, 2025 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 1, 2025 | BDSX Biodesix, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 15, 2025 | BDSX Biodesix, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Sep 15, 2025 | BDSX Biodesix, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Sep 11, 2025 | BDSX Biodesix, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 7, 2025 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 21, 2025 | BDSX Biodesix, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 13, 2025 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 17, 2025 | BDSX Biodesix, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 28, 2025 | BDSX Biodesix, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Mar 3, 2025 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 10, 2025 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 1, 2024 | BDSX Biodesix, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
20 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances